GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Giant Biogene Holding Co Ltd (HKSE:02367) » Definitions » Operating Income

Giant Biogene Holding Co (HKSE:02367) Operating Income : HK$1,821 Mil (TTM As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Giant Biogene Holding Co Operating Income?

Giant Biogene Holding Co's Operating Income for the six months ended in Dec. 2023 was HK$1,031 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1,821 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Giant Biogene Holding Co's Operating Income for the six months ended in Dec. 2023 was HK$1,031 Mil. Giant Biogene Holding Co's Revenue for the six months ended in Dec. 2023 was HK$2,098 Mil. Therefore, Giant Biogene Holding Co's Operating Margin % for the quarter that ended in Dec. 2023 was 49.14%.

Giant Biogene Holding Co's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Giant Biogene Holding Co's annualized ROC % for the quarter that ended in Dec. 2023 was 184.08%. Giant Biogene Holding Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 270.05%.


Giant Biogene Holding Co Operating Income Historical Data

The historical data trend for Giant Biogene Holding Co's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Giant Biogene Holding Co Operating Income Chart

Giant Biogene Holding Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Operating Income
754.07 961.87 1,140.80 1,316.19 1,821.00

Giant Biogene Holding Co Semi-Annual Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Operating Income Get a 7-Day Free Trial - 593.91 750.39 789.79 1,031.22

Giant Biogene Holding Co Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$1,821 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Giant Biogene Holding Co  (HKSE:02367) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Giant Biogene Holding Co's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=2062.43 * ( 1 - 19.32% )/( (848.877 + 959.043)/ 2 )
=1663.968524/903.96
=184.08 %

where

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4241.702 - 350.956 - ( 3041.869 - max(0, 367.771 - 3428.88+3041.869))
=848.877

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5439.448 - 537.915 - ( 4133.144 - max(0, 580.372 - 4522.862+4133.144))
=959.043

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Giant Biogene Holding Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=2120.97/( ( (663.48 + max(-63.249, 0)) + (907.325 + max(-270.7, 0)) )/ 2 )
=2120.97/( ( 663.48 + 907.325 )/ 2 )
=2120.97/785.4025
=270.05 %

where Working Capital is:

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(99.554 + 203.98 + 0.0010000000002037) - (350.956 + 0 + 15.828)
=-63.249

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(88.725 + 219.237 + 0) - (537.915 + 0 + 40.747)
=-270.7

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Giant Biogene Holding Co's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=1031.215/2098.355
=49.14 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Giant Biogene Holding Co Operating Income Related Terms

Thank you for viewing the detailed overview of Giant Biogene Holding Co's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Giant Biogene Holding Co (HKSE:02367) Business Description

Traded in Other Exchanges
N/A
Address
No. 1855, Shanglin Yuan 7th Road, Chang’an District, Shaanxi Province, Xi’an, CHN
Giant Biogene Holding Co Ltd design, develop and manufacture professional skin treatment products with recombinant collagen as the key bioactive ingredient. The company also develops and manufactures rare ginsenosides technology-based functional foods. The company utilizes proprietary synthetic biology technology to develop and manufacture multiple types of recombinant collagen and rare ginsenosides in-house. Bioactive ingredients offer a wealth of beauty and health properties such as skin repair, anti-aging, whitening, moisturizing and immunity improvement with a broad range of applications in the beauty and health sectors.
Executives
Refulgence Holding Limited 2201 Interest of corporation controlled by you
Juzi Holding Co., Ltd 2101 Beneficial owner
Fan Daidi 2201 Interest of corporation controlled by you
Yan Jianya 2202 Interest of your spouse
Yi Fang Da Ji Jin Guan Li You Xian Gong Si 2102 Investment manager
Yan Jianya 2101 Beneficial owner
Fan Daidi
Trident Trust Company (b.v.i.) Limited 2301 Trustee

Giant Biogene Holding Co (HKSE:02367) Headlines

No Headlines